Taysha Gene Therapies Inc · Q1 2023 earnings

Briefing

Reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Taysha Gene Therapies reported a net loss of $17.6 million for the first quarter of 2023, which was partially offset by revenue of $4.7 million from Astellas Transactions. The company's cash and cash equivalents were $63.4 million as of March 31, 2023, which is expected to support planned operations into the first quarter of 2024.

• Screening completed and dosing scheduled for the first potential subject in the Phase 1/2 REVEAL trial in Rett syndrome.
• Dosing of the first adult patient with TSHA-102 is expected in Q2 2023, with initial Phase 1/2 clinical data expected in Q2 2023.
• CTA submission to UK MHRA for TSHA-102 in pediatric patients with Rett syndrome expected in mid-2023, and IND application to U.S. FDA anticipated in H2 2023.
• A formal FDA meeting request submission to discuss the regulatory path forward for TSHA-120 in GAN expected in Q2 2023, with the meeting anticipated in Q3 2023.

Headline financials

Revenue & EPS history

Taysha continues to expect that its current cash resources will support planned operating expenses and capital requirements into the first quarter of 2024.